LFCRNasdaqPharmaceutical PreparationsFiscal year ends May 25
LIFECORE BIOMEDICAL, INC. DE
Financials through Q4 FY2025, quarter ended May 25, 2025Last filing: 10-Q on Aug 5, 2026
$6.39+0.01 (+0.16%)
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- –
- Dividend yield
- –
LIFECORE BIOMEDICAL, INC. DE revenue by segment
By business segment
| Revenue | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q3 23 | TTM Q2 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Other | – | – | – | – | – | – | – | – | – | – | $0 | $0 | – | – |
| Lifecore | – | – | – | – | – | – | – | – | – | – | $99.34M | $107.82M | – | – |
| Curation Foods | – | – | – | – | – | – | – | – | – | – | $106.07M | $107.39M | – | – |
| Reportable Segment | – | $128.87M | – | – | – | – | – | – | – | – | – | – | – | – |
By product or service
| Revenue | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q3 23 | TTM Q2 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CDMO | $91.66M | $90.10M | $95.67M | $97.19M | $95.26M | $96.62M | $91.41M | $87.12M | $79.65M | $76.38M | $74.85M | $81.64M | 67.8% | -3.8% |
| HA manufacturing | $43.61M | $38.77M | $34.64M | $33.67M | $33.19M | $31.65M | – | – | – | – | – | – | 32.2% | +31.4% |
| Contract development and manufacturing organization and Fermentation | – | – | – | – | – | – | – | – | – | – | $99.74M | $108.01M | – | – |
| Fermentation | – | – | – | – | – | – | – | – | $24.42M | $26.89M | $24.89M | $26.38M | – | – |
| Other | – | – | – | – | – | – | – | – | – | $0 | $493.00K | $915.00K | – | – |
| Olive oil and vinegars | – | – | – | – | – | – | – | – | – | – | – | $0 | – | – |
By region
| Revenue | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q3 23 | TTM Q2 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Switzerland | – | – | – | – | – | – | – | – | – | – | $18.00M | $19.40M | – | – |
| All other countries | – | – | – | – | – | – | – | – | – | – | $2.70M | $4.10M | – | – |
| Canada | – | – | – | – | – | – | – | – | – | – | $18.20M | $17.70M | – | – |
From the segment and revenue-disaggregation notes of Lifecore Biomedical, Inc. De's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.